NCT00317694View on ClinicalTrials.gov

Efficacy and Safety Study of Magnesium Iron Hydroxycarbonate for the Reduction of High Blood Phosphate in Hemodialysis Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

111

Participants

Timeline

Start Date

March 31, 2006

Primary Completion Date

June 30, 2007

Study Completion Date

June 30, 2007

Conditions
Chronic Kidney Failure
Interventions
DRUG

Fermagate

Film coated tablet 500mg

DRUG

Placebo

Oral administration, film coated tablet, 0mg

Trial Locations (15)

28208

Davita Dialysis Center, Charlotte

Southeast Renal Associates, Charlotte

71603

1614 West 42nd Street, Pine Bluff

72160

US Renal Care, Stuttgart

B9 5SS

Renal Unit, Birmingham Heartlands Hospital, Birmingham

BD5 0NA

St Lukes Hospital, Bradford

BS10 5NB

Richard Bright Renal Unit, Southmead Hospital, Bristol

CB2 2QQ

Addenbrookes Dialysis Centre, Addenbrookes Hospital, Cambridge

LE5 4PW

Renal Unit, Leicester General Hospital, Leicester

L14 3LB

Dialysis Unit, Broad Green Hospital, Liverpool

L7 8XP

Royal Liverpool University Hospital, Liverpool

NR4 7RF

General Medicine and Nephrology, Norfolk and Norwich University Hospital, Norwich

NG5 1PB

Nottingham Renal and Transplant Unit, Nottingham City Hospital, Nottingham

S5 7AU

Sheffield Kidney Unit, Northern General Hospital, Sheffield

SA6 6NL

Dept. of Nephrology, Morriston Hospital, Swansea

All Listed Sponsors
lead

Ineos Healthcare Limited

INDUSTRY

NCT00317694 - Efficacy and Safety Study of Magnesium Iron Hydroxycarbonate for the Reduction of High Blood Phosphate in Hemodialysis Patients | Biotech Hunter | Biotech Hunter